
|Videos|April 16, 2022
Venetoclax Monotherapy for the Treatment of Multiple Myeloma
Author(s)Shaji Kumar, MD, Jonathan L. Kaufman, MD
Sponsored in Part by AbbVie/Content Independently Developed by Targeted Oncology. Shaji Kumar, MD, describes the mechanism of action of BCL-2 inhibitor venetoclax and clinical trial data on its efficacy in multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5




























